Quarterly report · Q2
2934.TEDINET S100SM1Y
Period2023-06-01 → 2023-11-30
Filed2024-01-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥8.0bn | 2023-06-01 → 2023-11-30 | Cons. | Net sales |
| Revenue | ¥16.8bn | 2022-06-01 → 2023-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥9.1bn | 2022-06-01 → 2022-11-30 | Cons. | Net sales |
| Operating income | −¥221m | 2023-06-01 → 2023-11-30 | Cons. | Operating income |
| Operating income | −¥389m | 2022-06-01 → 2022-11-30 | Cons. | Operating income |
| Ordinary income | −¥232m | 2023-06-01 → 2023-11-30 | Cons. | Ordinary income |
| Ordinary income | −¥1.8bn | 2022-06-01 → 2023-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥403m | 2022-06-01 → 2022-11-30 | Cons. | Ordinary income |
| Profit before tax | −¥233m | 2023-06-01 → 2023-11-30 | Cons. | Income before income taxes |
| Profit before tax | −¥403m | 2022-06-01 → 2022-11-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥287m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.9bn | 2022-06-01 → 2023-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥354m | 2022-06-01 → 2022-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥284m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss |
| Net income | −¥321m | 2022-06-01 → 2022-11-30 | Cons. | Profit loss |
| Total assets | ¥7.4bn | at 2023-11-30 | Cons. | Assets |
| Total assets | ¥7.2bn | at 2023-05-31 | Cons. | Assets |
| Total assets | ¥7.9bn | at 2022-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥4.2bn | at 2023-11-30 | Cons. | Liabilities |
| Total liabilities | ¥4.5bn | at 2023-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥3.1bn | at 2023-11-30 | Cons. | Net assets |
| Net assets / equity | ¥2.7bn | at 2023-05-31 | Cons. | Net assets |
| Net assets / equity | ¥4.2bn | at 2022-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.3bn | at 2023-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.6bn | at 2023-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.3bn | at 2023-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.6bn | at 2023-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.8bn | at 2022-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2022-05-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥971m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.8bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥594m | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥300m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥800m | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥933m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.5bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.3bn | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-59.33 | 2023-06-01 → 2023-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-51.91 | 2023-09-01 → 2023-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-410.6 | 2022-06-01 → 2023-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-77.42 | 2022-06-01 → 2022-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-48.4 | 2022-09-01 → 2022-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 39.1% | at 2023-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.1% | at 2023-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.2% | at 2022-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-06-01 → 2023-11-30 | −¥115m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-06-01 → 2023-11-30 | −¥115m |
| Reconciling Itemsreconciling | segment profit | 2023-06-01 → 2023-11-30 | −¥290m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥2.4bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥2.3bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥114m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥19m |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥2.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥2.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥6m |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥3.7bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥3.7bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥958,000 |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥44m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-06-01 → 2023-11-30 | ¥8.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-06-01 → 2023-11-30 | ¥8.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥115m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-06-01 → 2023-11-30 | ¥69m |
| Reconciling Itemsreconciling | revenue | 2022-06-01 → 2022-11-30 | −¥84m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-06-01 → 2022-11-30 | −¥84m |
| Reconciling Itemsreconciling | segment profit | 2022-06-01 → 2022-11-30 | −¥277m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥3.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥2.9bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue intersegment | 2022-06-01 → 2022-11-30 | ¥84m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | segment profit | 2022-06-01 → 2022-11-30 | ¥55m |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥2.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥2.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | segment profit | 2022-06-01 → 2022-11-30 | ¥248m |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥4.2bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥4.2bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue intersegment | 2022-06-01 → 2022-11-30 | ¥181,000 |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | segment profit | 2022-06-01 → 2022-11-30 | −¥414m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-06-01 → 2022-11-30 | ¥9.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-06-01 → 2022-11-30 | ¥9.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-06-01 → 2022-11-30 | ¥84m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-06-01 → 2022-11-30 | −¥112m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 505
| Item | Context | Value | Unit |
|---|---|---|---|
| Increase decrease in allowance for doubtful accounts ope cf | CurrentYTDDuration | 3294000 | JPY |
| Increase decrease in provision for bonuses ope cf | Prior1YTDDuration | 21958000 | JPY |
| Increase decrease in provision for bonuses ope cf | CurrentYTDDuration | 9310000 | JPY |
| Increase decrease in provision for point card certificates ope cf | Prior1YTDDuration | 10532000 | JPY |
| Increase decrease in provision for point card certificates ope cf | CurrentYTDDuration | -11601000 | JPY |
| Interest and dividends income ope cf | Prior1YTDDuration | -107000 | JPY |
| Interest and dividends income ope cf | CurrentYTDDuration | -231000 | JPY |
| Interest expenses ope cf | Prior1YTDDuration | 5095000 | JPY |
| Interest expenses ope cf | CurrentYTDDuration | 10457000 | JPY |
| Issuance cost of subscription rights to shares ope cf | Prior1YTDDuration | 9384000 | JPY |
| Issuance cost of subscription rights to shares ope cf | CurrentYTDDuration | － | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1YTDDuration | 98582000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | CurrentYTDDuration | 164364000 | JPY |
| Decrease increase in inventories ope cf | Prior1YTDDuration | -120331000 | JPY |
| Decrease increase in inventories ope cf | CurrentYTDDuration | -532522000 | JPY |
| Decrease increase in prepaid expenses ope cf | Prior1YTDDuration | -38303000 | JPY |
| Decrease increase in prepaid expenses ope cf | CurrentYTDDuration | -15948000 | JPY |
| Decrease increase in consumption taxes refund recievable ope cf | Prior1YTDDuration | -31198000 | JPY |
| Decrease increase in consumption taxes refund recievable ope cf | CurrentYTDDuration | 168999000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1YTDDuration | -152733000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYTDDuration | 146204000 | JPY |
| Increase decrease in accounts payable other ope cf | Prior1YTDDuration | 164017000 | JPY |
| Increase decrease in accounts payable other ope cf | CurrentYTDDuration | -773366000 | JPY |
| Increase decrease in accrued expenses ope cf | Prior1YTDDuration | -6808000 | JPY |
| Increase decrease in accrued expenses ope cf | CurrentYTDDuration | -47441000 | JPY |
| Increase decrease in accrued consumption taxes ope cf | Prior1YTDDuration | -45092000 | JPY |
| Increase decrease in accrued consumption taxes ope cf | CurrentYTDDuration | 8729000 | JPY |
| Other net ope cf | Prior1YTDDuration | -6021000 | JPY |
| Other net ope cf | CurrentYTDDuration | -13631000 | JPY |
| Subtotal ope cf | Prior1YTDDuration | -357446000 | JPY |
| Subtotal ope cf | CurrentYTDDuration | -938390000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1YTDDuration | 107000 | JPY |
| Interest and dividends income received ope cf inv cf | CurrentYTDDuration | 231000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YTDDuration | -5075000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration | -10354000 | JPY |
| Income taxes paid ope cf | Prior1YTDDuration | -231340000 | JPY |
| Income taxes paid ope cf | CurrentYTDDuration | -51742000 | JPY |
| Income taxes refund ope cf | Prior1YTDDuration | － | JPY |
| Income taxes refund ope cf | CurrentYTDDuration | 29256000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | -593755000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | -970999000 | JPY |
| Payments into time deposits inv cf | Prior1YTDDuration | -75000000 | JPY |
| Payments into time deposits inv cf | CurrentYTDDuration | -50000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -63842000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -48596000 | JPY |
| Purchase of intangible assets inv cf | Prior1YTDDuration | － | JPY |
| Purchase of intangible assets inv cf | CurrentYTDDuration | -3520000 | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | Prior1YTDDuration | -576977000 | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | CurrentYTDDuration | -103453000 | JPY |
| Purchase of investment securities inv cf | Prior1YTDDuration | -40002000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |